Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Blood marker for diagnosing hepatic fibrosis and early cirrhosis

A blood marker, liver fibrosis technology, applied in the field of blood marker galectin 3, can solve problems such as complications

Inactive Publication Date: 2012-08-22
ANHUI SIZHENG MEDICAL TECH
View PDF2 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the current diagnosis of liver fibrosis still relies on biopsy of liver tissue, which is invasive and may cause fatal complications
At the same time, there is no obvious physiological discomfort in the early stage of liver fibrosis. It is unrealistic to perform periodic liver tissue biopsy to judge the occurrence of fibrosis. Therefore, there is an urgent need for a new method that uses blood as a test sample. To facilitate the early diagnosis of liver fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Preparation of mouse carbon tetrachloride liver fibrosis mouse model:

[0014] Four-week-old ICR mice were injected intraperitoneally with carbon tetrachloride dissolved in palm oil at a dose of 1 mg / kg body weight, twice a week for four consecutive weeks to obtain an animal model of significant liver tissue fibrosis.

[0015] Animals in the control group were injected with the same volume, the same number of times, and the same time of palm oil.

[0016] After the model is prepared, blood samples are obtained by taking blood from the eyeball in the first, second, third, and fourth weeks of modeling, and further centrifuged to obtain plasma samples for use.

[0017]

Embodiment 2

[0019] Detection of galectin-3 in experimental model plasma samples by ELISA:

[0020] 1. Coating: Dilute the antibody (purchased from Abcam, USA) with 0.05M pH9.0 carbonate coating buffer to a protein content of 1-10 μg / ml. Add 0.1ml to the reaction well of each polystyrene plate, overnight at 4°C. The next day, the solution in the well was discarded, and washed 3 times with washing buffer, 3 minutes each time. (referred to as washing, the same below).

[0021] 2. Adding samples: add 0.1ml of a certain dilution of the sample to be tested to the above-mentioned coated reaction wells, and incubate at 37°C for 1 hour. Then wash. (Make blank wells, negative control wells and positive control wells at the same time).

[0022] 3. Add avidin-labeled antibody: Add 0.1ml of freshly diluted avidin-labeled antibody (purchased from the US abcam company) (diluted after titration) to each reaction well. Incubate at 37°C for 0.5-1 hour and wash. 4. Adding biotin-labeled horser...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a blood marker for diagnosing hepatic fibrosis and early cirrhosis. The blood marker refers to galectin 3. The concentration of the galectin 3 in the blood is analyzed by using the blood marker through enzyme linked immune reaction so as to analyze and evaluate hepatic fibrosis and early cirrhosis. By using the blood as the detection sample, early diagnosis on hepatic fibrosis and early cirrhosis can be achieved conveniently and rapidly.

Description

technical field [0001] The invention relates to a blood marker galectin-3 for diagnosing liver fibrosis and early liver cirrhosis, belonging to the field of biomedicine. [0002] Background technique [0003] Liver fibrosis is a common pathological process of liver tissue damage to liver cirrhosis due to different reasons, including viral hepatitis, alcoholic hepatitis, fatty liver, and drug-induced liver injury. Liver cirrhosis is an irreversible liver tissue lesion, but when liver fibrosis has not developed into cirrhosis, timely drug intervention can inhibit the fibrosis process and restore liver tissue normally, avoiding the occurrence of liver cirrhosis. However, the current diagnosis of liver fibrosis still relies on biopsy of liver tissue, which is invasive and may cause fatal complications. At the same time, there is no obvious physiological discomfort in the early stage of liver fibrosis. It is unrealistic to perform periodic liver tissue biopsy to judge the occur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
Inventor 董磊
Owner ANHUI SIZHENG MEDICAL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com